Chronic Kidney Disease Clinical Trial
Official title:
A Phase I Randomized Double-blind Placebo-controlled Study With 2 Separate Cohorts to Assess the Safety, Tolerability and Pharmacokinetics of Verinurad and Allopurinol in Healthy Asian and Chinese Subjects
Verified date | May 2019 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, placebo controlled, double-blind study with two separate cohorts to
assess safety, tolerability and pharmacokinetics of verinurad and allopurinol in healthy
subjects.
In cohort 1, twelve Asian subjects will be treated with allopurinol 300mg for 7 days followed
by either allopurinol 300mg and verinurad 24mg or matching placebo for 7 days.
In Cohort 2, nine Chinese subjects will be treated with allopurinol 300mg for 7 days followed
by allopurinol 300mg and verinurad 12mg administered on 7 out of 8 days.
Status | Completed |
Enrollment | 6 |
Est. completion date | April 26, 2019 |
Est. primary completion date | April 26, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Provision of signed and dated, written informed consent prior to any study specific procedures. - Applicable only to Cohort 1: Healthy male and female Asian subjects aged 18 to 50 years (inclusive) at the Screening Visit with suitable veins for cannulation or repeated venipuncture. A subject will be considered Asian if the subject and both of the subject's parents are part of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam). - Applicable only to Cohort 2: Healthy male and female Chinese subjects aged 18 to 50 years (inclusive) at the Screening Visit with suitable veins for cannulation or repeated venipuncture. A subject will be considered Chinese if: - Both parents and all grandparents are Chinese, and - Subject was born in China, and - Subject has not lived outside China for more than 10 years. - Subject has a sUA acid level > 4.0 mg/dL at the Screening Visit. The assessment may be repeated once during the Screening Period. - Females must have a negative pregnancy test at the Screening Visit and Day -7, must not be lactating and must be: 1. Of non-childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria: - Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle-stimulating hormone (FSH) levels in the post-menopausal range (FSH levels > 40 IU/mL). - Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. 2. OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period. Exclusion Criteria: - Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, at the Screening Visit as judged by the Investigator including: 1. Alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN); 2. Aspartate aminotransferase (AST) >1.5 x ULN; 3. Bilirubin (total) > 1.5 x ULN; and 4. Gamma glutamyl transpeptidase (GGT) >1.5 x ULN. If any these tests are out-of-range the test can be repeated once at the Screening Visit at the discretion of the Investigator. - Known carrier of the Human Leukocyte Antigen-B (HLA-B) *58:01 allele. - Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody. - Suspected or known Gilbert's syndrome. - Current smokers or those who have smoked or used nicotine products (including e-cigarettes within the previous 3 months). - Positive screen for drugs of abuse, cotinine (nicotine) or alcohol at the Screening Visit or on Day -7. - Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of investigational product or within 5 half-lives (whichever is longer). The use of hormonal contraception therapy and hormonal replacement therapy for females are permitted. - Has received another new chemical or biological entity (defined as a compound which has not been approved for marketing in the US) within 30 days or within 5 half-lives (whichever is longer) of the first administration of investigational drug in this study. - Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives. - Subjects who are vegans or have medical dietary restrictions. |
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Glendale | California |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Parexel |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events | To assess the safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/Early discontinuation visit (EDV) (7-14 Days Post-last PK Sample) | |
Primary | Number of participants with abnormal findings in electrocardiography (ECG) | To assess abnormal resting digital 12-lead electrocardiograms as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | |
Primary | Number of participants with abnormal pulse rate | To assess abnormal pulse rate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | |
Primary | Number of participants with abnormal hematology | To assess white blood cell count (WBC), red blood cell count (RBC), neutrophils absolute count, lymphocytes absolute count, monocytes absolute count, eosinophils absolute count, basophils absolute count, platelets, and reticulocytes absolute count as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | |
Primary | Number of participants with abnormal blood pressure (systolic and diastolic) | To assess abnormal blood pressure (systolic and diastolic) as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)] | |
Primary | Number of participants with abnormal physical examination | To assess safety and tolerability by assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK sample)] | |
Primary | Number of participants with abnormal electrolytes | To assess serum level of sodium, potassium, calcium (total), and phosphate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK smaple)] | |
Primary | Number of participants with abnormal hemoglobin (Hb) | To assess Hb as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample) | |
Primary | Number of participants with abnormal hematocrit | To assess hematocrit as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample) | |
Primary | Number of participants with abnormal Mean corpuscular volume (MCV) | To assess MCV as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample) | |
Primary | Number of participants with abnormal mean corpuscular hemoglobin (MCH) | To assess MCH as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample) | |
Primary | Number of participants with abnormal mean corpuscular hemoglobin concentration (MCHC) | To assess MCHC as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants. | From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample) | |
Primary | Number of participants with abnormal clinical chemistry | To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal clinical chemistry values. The laboratory variables to be measured are: bilirubin, creatinine, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cystatin C, gamma glutamyl transpeptidase, urea and uric acid. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | |
Primary | Number of participants with abnormal urinalysis. | To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal urinalysis values. The laboratory variables to be measured are: protein, glucose, blood, uric acid, pH, sodium, creatinine, and cystatin C. | From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | |
Secondary | Area under plasma concentration-time curve from zero to infinity (AUC), AUC(0-t), AUC(0-24), and AUCt | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2). | |
Secondary | Observed concentration and percentage change from baseline in serum uric acid | To evaluate serum uric acid of verinurad and allopurinol treatment in terms of the number of participants with observed concentration and percentage change from baseline in serum uric acid. | On Day -1: -24, -21, -18, and -12 hours prior to dosing on Day 1. On Days 1, 7 and 9 (Pre-dose, 3, 6, 12, and 24 hours post-dose). | |
Secondary | Observed concentration and percentage change from baseline in urine uric acid | To evaluate urine uric acid of verinurad and allopurinol treatment in terms of the number of participants with observed concentration and percentage change from baseline in urine uric acid. | On Day -1: baseline collection of urine: -24 to -22 h, -22 h to -20 h, -18 h to -16 h, -16 h to - 12 h and -12 h to 0 h prior to dosing on Day 1, on Days 1, 7 and 9 (0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h, and 12-24 h post-dose). | |
Secondary | Maximum observed plasma concentration (Cmax) and Minimum observed plasma concentration (Cmin) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2) | |
Secondary | Time to reach maximum observed plasma concentration (tmax) and Time of last measurable concentration (tlast) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2). | |
Secondary | Apparent total body clearance of drug from plasma after extravascular administration across the dosing interval (CL/F) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2) | |
Secondary | Half-life associated with terminal slope (?z) of a semi-logarithmic concentration-time curve (t½?z) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2) | |
Secondary | Apparent volume of distribution based on the terminal phase (Vz/F) and Apparent volume of distribution during the terminal phase after extravascular administration (Vss/F) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2) | |
Secondary | Mean residence time (MRT) | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 1 | |
Secondary | Accumulation ratio for Cmax and AUCt | To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants. | On Day 7 (Cohort 1) or Day 9 (Cohort 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |